MindRank AI Recognized as a Digital Health Front-Runner and CEO Niu Zhangming Honored as Rising Star in Zhangjiang Life Sciences-VCBeat

November 16-18, 2024China Pharmaceutical Industry Development Conference and Shanghai International Biomedical Industry WeekHeld concurrently at the Zhangjiang Science Hall in Shanghai. The conference and industry week, themed "Co-creation, Sharing, Win-win: Joining Hands for a New Future," focus on cutting-edge technological innovation in China's pharmaceutical industry and global pharmaceutical cooperation. During the industry week, MindRank was awarded two major industry awards for its innovation-driven AI drug discovery practices.

On the afternoon of November 17, at the Zhangjiang Collaborative Innovation Forum, the Zhangjiang Life Science and Health Industry Annual Rising Star Awards were officially announced, with 8 outstanding rising stars receiving this honor."MindRank Founder and CEO Zhangming Niu Selected as '2024 Zhangjiang Life Science Industry Annual Rising Star'"

Under the guidance and support of the Pudong New Area Talent Work Bureau and the Pudong New Area Science and Technology and Economy Commission, the Newcomer Awards event has been successfully held for three consecutive years. It aims to select and honor a group of annual rising figures and companies, promote the spirit of innovation, highlight innovative practices and achievements, set benchmarks for the industry, and lead the future.

On the same day, at the Biomedical Industry Investment and Financing Forum, the second China Biomedical Pioneers List was released, and "MindRank" was selected."2024 China Biomedical Front-Runners Digital Healthcare 100 Strong"

The selection of this list was initiated by the Shanghai Biomedical Science and Technology Industry Promotion Center, focusing on three major directions: biopharmaceuticals, medical devices, and digital healthcare. The selection process involved 35,000 companies with a total of five million data points and conducted a comprehensive evaluation based on dimensions such as corporate strategy, products, competition, business, team, and value. The aim is to explore new drivers, new engines, and new vitality for industrial development, establishing a benchmark for industry trends.

Currently, utilizing a self-developed and innovatively upgraded industrial-grade one-stop AI-driven innovative drug discovery platform, MindRank has launched its first self-developed GLP-1RA small molecule oral new drug.MDR-001 has been efficiently advanced to Phase IIb clinical research,Multiple oncology and metabolic drugs are undergoing IND-Enabling studies. Upholding the philosophy and vision of "Technology for Good," MindRank is committed to...Enable more innovative drugs to benefit public health as soon as possible.